SCA Pharma, which provides high-quality sterile admixture services to hospitals and health-care facilities nationwide, has named Scott Luce as Chief Executive Officer.
SCA Pharma has signed an agreement with Kit Check™, a leader in automated and intelligent medication management solutions, allowing the company to add Kit Check’s embedded radio frequency identification (RFID) tag to all of its products, further ensuring the safety of its products for customers. SCA Pharma is the first 503B to use Kit Check’s tunnel association technology and register all drugs in the cloud-based registry.
With this Kit Check technology, SCA Pharma will continue to deliver on its mission to offer hospitals solutions that improve the efficiency and accuracy of OR medication tracking processes. SCA Pharma’s extensive product catalog will be combined with Kit Check’s advancements in RFID tagging technology to present dynamic products to its customers. All SCA Pharma products will now be “ready to go” right out of the box, and the embedded RFID tag will save room in OR trays, allowing for more ease of use.
“Over the years we’ve been working together, Kit Check’s technology has allowed us to provide customers with stronger, safer products,” said Milton Boyer, CEO of SCA Pharma. “With the implementation of RFID tracking tags on all SCA Pharma products, our customers will have even more confidence in their overall OR medication tracking processes and can be sure that any potential diversion attempts will be halted at the first sign of abnormality.”
Kit Check is a provider of automated medication tracking and diversion detection solutions for hospital pharmacies in the U.S. Their medication intelligence platforms provide item level visibility, workflow simplicity and actionable analytics, helping stakeholders deliver the right medicine to the right patient at the right time.